SYH2053
SYH2053 has been studied in 1 paper since 2026: 1 trial in people; 1 in the past year. The newest paper, Oct 26, 2026: “Efficacy and safety of SYH2053 in patients with primary hypercholesterolemia or mixed dyslipidemia: a phase II, multicenter, randomized, double-blind, placebo- and active-controlled trial”.
1 paper studies it2 findingsUpdated
1 new paper in 30 daysSee all 1 papers on SYH2053
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country; 3 trials, none about aging, 1 with no results posted.
“At Day 180, SYH2053-300 mg group exhibited the numerically greatest reductions in LDL-C and PCSK9 among the five groups”
None of its findings points the other way.
- 1 lab in 1 country
- 3 trials, none about aging, 1 with no results posted
- 2 of 2 findings with company ties
- 3 of 3 trials sponsored by its developers
- Human trial1
Studies in people
1 study gave SYH2053 to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases LDL-C-52.94% versus placebo (95% CI -62.16 to -43.73; p < 0.0001) down: Decreases PCSK9-91.50% versus placebo (95% CI -99.80 to -83.21; p < 0.0001) | Randomized trial180 days | 156 people18–75 yearsPrimary hypercholesterolemia or mixed dyslipidemia; placebo-adjusted comparison | ESC Congress 2026 abstract, Oct 26, 2026 |
What did studies of SYH2053 find?
2Studies of SYH2053 measured 2 outcomes: PCSK9 and LDL-C.
PCSK9
downin humans1
1 study
PCSK9
downin humans1
SYH2053 decreases PCSK9 in humans (Primary hypercholesterolemia or mixed dyslipidemia; placebo-adjusted comparison) (-91.50% versus placebo (95% CI -99.80 to -83.21; p < 0.0001)).
“At Day 180, SYH2053-300 mg group exhibited the numerically greatest reductions in LDL-C and PCSK9 among the five groups”
Human trialPrimary hypercholesterolemia or mixed dyslipidemia; placebo-adjusted comparisoninjection300 mg180 days
ESC Congress 2026 abstract
LDL-C
downin humans1
1 study
LDL-C
downin humans1
SYH2053 decreases LDL-C in humans (Primary hypercholesterolemia or mixed dyslipidemia; placebo-adjusted comparison) (-52.94% versus placebo (95% CI -62.16 to -43.73; p < 0.0001)).
“At Day 180, SYH2053-300 mg group exhibited the numerically greatest reductions in LDL-C and PCSK9 among the five groups”
Human trialPrimary hypercholesterolemia or mixed dyslipidemia; placebo-adjusted comparisoninjection300 mg180 days
ESC Congress 2026 abstract
Who is developing SYH2053?
1 company: CSPC Zhongnuo Pharmaceutical (Shijiazhuang).
- Companies
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang)Phase 2hypercholesterolemia and mixed hyperlipidemia, hepatic impairment
Trial sponsors
Company3 trialsPhase 2204 people